Help us: Donate
Follow us on:
×

Patrick Deane

Patrick Deane

About Patrick Deane

As an undergraduate of Human Biosciences at Plymouth University, aging research has been Patrick’s passion for a long time now. While he has aspirations to later directly join the research effort, for now, he provides the community with educational articles, spreading knowledge of the biology behind the aging process while he himself learns.

Related Organizations

Articles from this author

June 18, 2020
The world is reeling from the SARS-CoV-2 (COVID-19) pandemic, which has both had severe economic and humanitarian effects. As we continue to practice social distancing, we should ask ourselves: How can we avoid similar pandemics in the future? Aging and infectious disease are linked As we have discussed previously, aging is a major contributor to...
September 24, 2019
The ability to create synthetic organs has long been desired in medicine. If we could make synthetic organs for patients from their own cells, we could replace injured or damaged organs without risking the body rejecting the organ. This would have huge implications for the treatment of liver and kidney diseases, among others. For years,...
August 12, 2019
Today, we have to share some bad news about Organovo and its liver tissue bioprinting program. Present state and future steps Organovo, a biotechnology company currently valued at $45M and most well-known for researching bioprinting technologies - the creation of artificial organs - has recently announced that it is suspending its artificial liver tissue program...
August 07, 2019
A study on animals with autoimmune myocarditis was recently released in the journal Cell Reports [1], showing the impact of heart inflammation on the types of immune cell that are formed in the heart. This could have a significant impact on our understanding of cardiac aging. What is myocarditis and how is it relevant to...
July 22, 2019
Today, we want to highlight a recent human trial of the popular supplement nicotinamide riboside, a compound that has been shown in mice to restore NAD+ levels. The compound has had impressive results against some aspects of aging in mouse studies, and there is now some more data for NR in humans [1]. What is...
June 21, 2019
Note: Patrick Deane holds shares in Gensight Biologics (EPA: SIGHT). A trial with damagingly positive results Gensight Biologics, a company researching - among other things - the movement of mitochondrial genetic information to the nucleus to treat hereditary genetic diseases (a strategy that could also have an impact on aging according to the SENS Research...